Nissen, S.E., Nicholls, S.J., Sipahi, I., Libby, P., Raichlen, J.S., Ballantyne, C.M., Davignon, J., Erbel, R., Fruchart, J.C., Tardif, J.C., Schoenhagen, P., Crowe, T., Cain, V., Wolski, K., Goormastic, M., Tuzcu, E.M., The ASTEROID Investigators, et al. (2006) Effect of very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis—The ASTEROID Trial. Journal of the American Medical Association, 295, 1556- 1565.
https://doi.org/10.1001/jama.295.13.jpc60002

has been cited by the following article:

• TITLE: Prevention of Coronary Heart Disease: A Translational Clinical Challenge

  AUTHORS: Julie Giannini, Janae Padilla, Robert Philip Eaton, Kristen Gonzales, David S. Schade

  KEYWORDS: Asymptomatic Cardiovascular Disease, Coronary Artery Calcium Scan, Preventive Medical Therapy, Cardiovascular Risk

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.12 No.1, January 21, 2022

  ABSTRACT: Introduction: Atherosclerotic cardiovascular disease is a dysmetabolic medical condition resulting in the #1 cause of morbidity and mortality in theUnitedStates. Coronary Artery Calcium (CAC) CT non-invasively identifies atherosclerosis in asymptomatic individuals. This translational study tested the hypothesis that clinically overtcardiovascular disease can be prevented in asymptomatic individuals in a medical clinic. Methods: Two hundred and six asymptomatic adults requested a CAC scan to identify subclinical heart disease. Individuals with a positive CAC score > 1 (n = 125) were prescribed targeted medical therapy to reverse their atherosclerosis. The goal was to achievean LDL Cholesterol (LDL-C) ≤ 60 mg/dl. One hundred and ten individuals reached thisgoal (67 male, 43 female) receiving 10 mg/d of rosuvastatin and 10 mg/d ofezetimibe plus a low cholesterol diet. Other fifteen individuals with positive CAC scores did not achieve this LDL-C goal. Results: In the group following medical therapy and achieving an LDL-C ≤ 60 mg/dl, no cardiovascular events were observed during a maximum observation period of 5 years (mean observation time = 3.6 years). Based on previously published CVD outcome data in individuals with similar CAC scores, 12.6 cardiovascular events were expected.Two of fifteen individuals with positive CAC scores not following medicaltherapy had a cardiovascular event. None of the 81 individuals with a zero score hada cardiovascular event during follow-up. No adverse effects of therapy occurred. Conclusion: In a medical clinic, adult population with positive CAC scores and an LDL-C ≤ 60 mg/dl, targeted medical therapy prevented overt cardiovasculardisease. These results should encourage other physicians to aggressively treat atherosclerotic cardiovascular disease in their clinic populations.